Showing results (41-50 of 185) with videos related to
Sort By:
Pageof 19
International Journal of General Medicine|December 1, 2022
Value Insider Season 1 Episode 5: What Other Aspects of Value May Be Relevant? (Societal Impact) [Podcast]Louis P Garrison, Elisabeth Sophia Hartgers-Gubbels, Michael ChambersJournal of Managed Care & Specialty Pharmacy|October 31, 2019
Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care PharmacyLouis P Garrison, Peter J Neumann, Richard J WillkeValue in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 26, 2018
A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1]Peter J Neumann, Richard J Willke, Louis P GarrisonBMC Research Notes|March 18, 2010
A review of data needed to parameterize a dynamic model of measles in developing countriesEmily K Szusz, Louis P Garrison, Chris T BauchValue in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2019
Defining and Managing High-Priced Cures: Healthcare Payers' OpinionsKai Yeung, Kangho Suh, Louis P Garrison, et al.Value in Health Regional Issues|December 12, 2018
Value-Based Pricing in Latin America: How Far Away Are We?Aurelio Mejía, Ramiro Gilardino, Finn Børlum Kristensen, et al.The Journal of Urology|April 8, 2014
Resource utilization and costs associated with the diagnostic evaluation of nonrefluxing primary hydronephrosis in infantsArdavan Akhavan, Margarett Shnorhavorian, Louis P Garrison, et al.Expert Review of Pharmacoeconomics & Outcomes Research|December 21, 2012
The cost offsets and cost-effectiveness associated with pegylated drugs: a review of the literatureRussell Becker, Carole Dembek, Leigh Ann White, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 8, 2024
Evaluating Policies of Expanding Versus Restricting First-Line Treatment Choices: A Cost-Effectiveness Analysis FrameworkBoshen Jiao, Josh J Carlson, Louis P Garrison, et al.Pharmacoeconomics|April 12, 2006
Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UKBeate Sander, Frederick G Hayden, Marlene Gyldmark, et al.Pageof 19